Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1004976 | 0.78 | ALDH1A1 (0.52) | ALDH1A1MAPTL3MBTL1GAACA1 | |
| SCHEMBL13545147 | 0.76 | PTGS1 (0.44) | ALDH1A1GAACA1CA2CA4 | |
| SCHEMBL9816728 | 0.75 | NPC1 (0.47) | ALDH1A1GAACA1CA2CA4 | |
| Water SCHEMBL9787126 | 0.73 | CYP2D6 (0.47) | ALDH1A1MAPTL3MBTL1TDP1GAA | |
| SCHEMBL8639644 | 0.73 | ALDH1A1 (0.46) | ALDH1A1MAPTL3MBTL1CYP1A2CYP2C9 | |
| SCHEMBL1654265 | 0.72 | MAPT (0.48) | ALDH1A1MAPTL3MBTL1GAACYP1A2 | |
| Calcium SCHEMBL31193385 | 0.71 | ALDH1A1 (0.45) | ALDH1A1MAPTL3MBTL1CYP1A2CYP2C9 | |
| Bicarbonate SCHEMBL8638060 | 0.70 | ALDH1A1 (0.44) | ALDH1A1MAPTL3MBTL1CYP1A2CYP2C9 | |
| SCHEMBL17449502 | 0.69 | ALDH1A1 (0.36) | ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL8393094 | 0.69 | TP53 (0.39) | ALDH1A1MAPTL3MBTL1GAACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111936468-B | Compounds with anticancer activity | 协和麒麟株式会社 | 2024-03-08 | — | — | CN | disclosed |
| US-20220378923-A1 | BET DEGRADER | KYOWA KIRIN CO., LTD. (JP) | 2022-12-01 | — | — | US | disclosed |
| EP-4039333-A1 | BET DEGRADER | Kyowa Kirin Co., Ltd. (JP) | 2022-08-10 | — | — | EP | disclosed |
| CN-114502534-A | BET degradant | 协和麒麟株式会社 | 2022-05-13 | — | — | CN | disclosed |
| WO-2021065980-A1 | BET DEGRADER | 協和キリン株式会社 | 2021-04-08 | — | — | WO | disclosed |
| CN-111936468-A | Compounds with anti-cancer activity | 协和麒麟株式会社 | 2020-11-13 | — | — | CN | disclosed |
| WO-2019189778-A1 | COMPOUND WITH ANTICANCER ACTIVITY | 協和発酵キリン株式会社 | 2019-10-03 | — | — | WO | disclosed |
| EP-1100492-B1 | INDOLE sPLA2 INHIBITORS | LILLY CO ELI (US) | 2006-05-24 | — | — | EP | disclosed |
| US-6617460-B1 | 5-hydrocarbylsulfoxy-4,5,6,7-tetrahydroindol-4-one intermediates useful in the preparation of 1H-indole-3-glyoxamides. | ELI LILLY AND COMPANY | 2003-09-09 | — | — | US | disclosed |
| US-6570023-B1 | Chemical intermediate for drug to threat sepsis shock, rheumatic diseases | ELI LILLY AND COMPANY | 2003-05-27 | — | — | US | disclosed |
| EP-1119546-A1 | PROCESS FOR PREPARING TOLUENESULFINATES | ELI LILLY AND COMPANY (US) | 2001-08-01 | — | — | EP | disclosed |
| EP-1119549-A1 | PROCESS FOR PREPARING 4-SUBSTITUTED-1H-INDOLE-3-GLYOXAMIDES | ELI LILLY AND COMPANY (US) | 2001-08-01 | — | — | EP | disclosed |
| US-6265591-B1 | HALOGENATING KETO ESTER COMPOUND; HYDROLYSIS AND DECARBOXYLATION; ALKYLATING; AMINATION AND DEHYDRATION TO FORM TRIKETO COMPOUND; AMINATING; OXIDATION, ALKYLATING; REACTING INDOLE DERIVATIVE WITH OXALYL CHLORIDE AND AMMONIA | ELI LILLY AND COMPANY | 2001-07-24 | — | — | US | disclosed |
| EP-1100492-A1 | INDOLE sPLA 2? INHIBITORS | Eli Lilly & Company (US) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000021929-A1 | PROCESS FOR PREPARING 4-SUBSTITUTED-1H-INDOLE-3-GLYOXAMIDES | ELI LILLY AND COMPANY (US) | 2000-04-20 | — | — | WO | disclosed |
| WO-2000021923-A1 | PROCESS FOR PREPARING TOLUENESULFINATES | ELI LILLY AND COMPANY (US) | 2000-04-20 | — | — | WO | disclosed |
| WO-2000007590-A1 | INDOLE sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2000-02-17 | — | — | WO | disclosed |
| US-5986106-A | Process for preparing 4-substituted-1H-indole-3-glyoxamides | ELI LILLY AND COMPANY (US) | 1999-11-16 | — | — | US | disclosed |
| WO-1999000360-A1 | PROCESS FOR PREPARING 4-SUBSTITUTED-1H-INDOLE-3-GLYOXAMIDES | ELI LILLY AND COMPANY (US) | 1999-01-07 | — | — | WO | disclosed |
| EP-0887342-A2 | Process for preparing 4-substituted-1H-indole-3-glyoxamides | ELI LILLY AND COMPANY (US) | 1998-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220378923-A1 | BET DEGRADER | BET1, BRD4, BICRA | ALDH1A1 3226/4885MAPT 1478/4885L3MBTL1 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.